Omni’s focus:
Specialty generic and branded pharmaceuticals featuring drug delivery systems that are difficult to develop, manufacture, and replicate for regulated markets, emerging markets and China.
Current systems:Inhalation dry powder, nasal and HFA aerosol, and sustained release capsules and tablets.
Regulated market experience
Senior R&D managers with proven track records in bringing products to the U.S. market on behalf of top global drug makers.
Independent or Partnered:
Develops and manufactures drugs independently or with partners, including CRO, co-development and out-licensing opportunities.
Please contact: szeng@omni-pharma.com Shaochuan Zeng, Chief Operating Officer